Lower versus higher oxygenation targets in critically ill patients with severe hypoxaemia: secondary Bayesian analysis to explore heterogeneous treatment effects in the Handling Oxygenation Targets in the Intensive Care Unit (HOT-ICU) trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 453 KB, PDF-dokument

Background: In the Handling Oxygenation Targets in the Intensive Care Unit (HOT-ICU) trial, a lower (8 kPa) vs a higher (12 kPa) PaO2 target did not affect mortality amongst critically ill adult patients. We used Bayesian statistics to evaluate any heterogeneity in the effect of oxygenation targets on mortality between different patient groups within the HOT-ICU trial. Methods: We analysed 90-day all-cause mortality using adjusted Bayesian logistic regression models, and assessed heterogeneous treatment effects according to four selected baseline variables using both hierarchical models of subgroups and models with interactions on the continuous scales. Results are presented as mortality probability (%) and relative risk (RR) with 95% credibility intervals (CrI). Results: All 2888 patients in the intention-to-treat cohort of the HOT-ICU trial were included. The adjusted 90-day mortality rates were 43.0% (CrI: 38.3–47.8%) and 42.3% (CrI: 37.7–47.1%) in the lower and higher oxygenation groups, respectively (RR 1.02 [CrI: 0.93–1.11]), with 36.5% probability of an RR <1.00. Analyses of heterogeneous treatment effects suggested a dose–response relationship between baseline norepinephrine dose and increased mortality with the lower oxygenation target, with 95% probability of increased mortality associated with the lower oxygenation target as norepinephrine doses increased. Conclusions: A lower oxygenation target was unlikely to affect overall mortality amongst critically ill adult patients with acute hypoxaemic respiratory failure. However, our results suggest an increasing mortality risk for patients with a lower oxygen target as the baseline norepinephrine dose increases. These findings warrant additional investigation. Clinical trial registration: NCT03174002.

OriginalsprogEngelsk
TidsskriftBritish Journal of Anaesthesia
Vol/bind128
Udgave nummer1
Sider (fra-til)55-64
Antal sider11
ISSN0007-0912
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
The Department of Intensive Care at Rigshospitalet has received funding for other projects from the Novo Nordisk Foundation, Pfizer, and Fresenius Kabi.Innovation Fund Denmark (4108-00011A); Aalborg University Hospital; Regions of Denmark (EMN-2017-00901 and EMN-2019-01055); Obel Family Foundation (25457); Danish Society of Anaesthesiology and Intensive Care Medicine; Intensive Care Symposium Hindsgavl.

Funding Information:
The Department of Intensive Care at Rigshospitalet has received funding for other projects from the Novo Nordisk Foundation , Pfizer , and Fresenius Kabi .

Publisher Copyright:
© 2021 The Author(s)

ID: 286996148